Related references
Note: Only part of the references are listed.Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
Jedidiah Morton et al.
DIABETOLOGIA (2023)
Global accessibility of therapeutics for diabetes mellitus
Michael Fralick et al.
NATURE REVIEWS ENDOCRINOLOGY (2022)
Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes
Meng-Ting Wang et al.
DIABETES CARE (2022)
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2022)
Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications
David T. Liss et al.
AMERICAN JOURNAL OF MANAGED CARE (2021)
Principles of confounder selection
Tyler J. VanderWeele
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
Ruth L. M. Cordiner et al.
DIABETES OBESITY & METABOLISM (2019)
Long-term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second-line Type 2 diabetes mellitus treatment in a US veteran population
W. R. Powell et al.
DIABETIC MEDICINE (2019)
Instrumental variables estimation under a structural Cox model
Torben Martinussen et al.
BIOSTATISTICS (2019)
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
Antonios Douros et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
Antonios Douros et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Do sulphonylureas still have a place in clinical practice?
Kamlesh Khunti et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
A review of instrumental variable estimators for Mendelian randomization
Stephen Burgess et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2017)
Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas
Berhanu Alemayehu et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
Julia Hippisley-Cox et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
Julia Hippisley-Cox et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Instrumental variables estimation of exposure effects on a time-to-event endpoint using structural cumulative survival models
Torben Martinussen et al.
BIOMETRICS (2017)
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
Antonios Douros et al.
DIABETES CARE (2017)
Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
Laurent Azoulay et al.
DIABETES CARE (2017)
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
Jan W. Eriksson et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Instrumental Variable Estimation in a Survival Context
Eric J. Tchetgen Tchetgen et al.
EPIDEMIOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Instrumental variable methods for causal inference
Michael Baiocchi et al.
STATISTICS IN MEDICINE (2014)
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Jie Hong et al.
DIABETES CARE (2013)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Instrumental variable methods in comparative safety and effectiveness research
M. Alan Brookhart et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
A diabetes outcome progression trial (ADOPT)
G Viberti et al.
DIABETES CARE (2002)
Share Paper
